Udg Healthcare Plc (UDHCF) 7.5549 $UDHCF Ashfield

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Udg Healthcare Plc (UDHCF) 7.5549 $UDHCF

Ashfield Launches Global Impact on Society Initiative
PR Newswire - Wed Aug 10, 3:00AM CDT
'Ashfield Cares' to Actively Support Charities and Programmes Through Fundraising, Time and Skills

Ashfield Commercial and Medical Services to move to new US Corporate Headquarters
PR Newswire - Thu Jul 28, 5:00AM CDT
Ashfield Commercial and Medical Services, part of UDG Healthcare plc, recently announced plans to move its corporate office to 1110 Virginia Drive, Fort Washington, PA, due to the continuing expansion of the business. The new office, situated in Philadelphia's northwestern suburbs, is over 80,000 sq.ft. which is 60% larger than the current Ashfield workspace. The expected move is scheduled for March 2017 after construction of the new space is completed in February.

Pharma Contract Sales Industry and Market: Trends and Forecasts 2015-2025 - Reportlinker Review
PR Newswire - Tue Oct 27, 7:45PM CDT
Report DetailsOutsourced selling of medicines - how to find trends, opportunities and potential revenuesWhat's the future of outsourcing pharma sales activities? For prescription drugs, get new forecasts for contracted promotional activities. Stay ahead, then, for data. There you explore business results, progress, trends, strategies and predicted revenues.Visiongain's updated report shows what's possible for those pharmaceutical services. Avoid missing out on opportunities. Instead explore advances in medical detailing and potential gains for contract sales organisations (CSOs).Please read on, then, to investigate that expanding healthcare industry, seeing what its future could be worth. For that outsourcing you assess expected developments.Forecasts and other information showing opportunity in pharmaceutical sales contractingProgress worldwide in healthcare expands use of out-contracted services for promoting and selling human medicines. There see what's possible.Besides forecasting revenues to 2025, the new analysis shows historical data, recent results, growth rates and market shares. There you gain feel for companies' outlooks and potentials. You also get 77 tables, 64 charts and three interviews with that industry.Knowledge to help your work and save time, benefiting your influenceOur study shows you revenue predictions to 2025 at overall world, submarket and national level. For those service offerings you investigate where money lies. Find what's happening.And avoid struggles to find business information on outsourced drug selling. Our report helps your research, analyses and decisions for medical sales. Save time, too, and stay ahead.Also - by gaining in knowledge of the present and future - benefit your authority through increased technological and commercial insight.And the following sections highlight, in detail, what the new investigation gives you.Forecasting of that world market and its segments - what's likely to happen?What're the secrets of that industry's progress? And what's its potential? Discover in our report overall world revenue to 2025 for contract pharma sales operations.Also see individual predictions of revenues to 2025 for 11 submarkets at world level:- Field sales (detailing)- Non-personal promotion, also with sub-forecasting for teledetailing, e-detailing and other selling functions- Medical education- Sample management activities- Other outsourced promotional services.And get forecasts by therapeutic application:- Cardiovascular disease therapies- Metabolic disorder treatments- Cancer-treating agents.There you assess prospects for outsourced medicine sales, hearing where you can gain. Investigate competition and increasing revenues. So discover lucrative possibilities for syndicated pharma sales teams and related promotional activities.Our investigation also shows you geographical predictions for CSOs and their teams.Healthcare in national markets - commercial outlooks for medical sales contractingThat study shows countries having great potential for those outsourced and off-shored selling operations. See where and how you could profit, assessing predicted revenues.Our analyses show you individual revenue forecasts to 2025 for 11 national markets:- United States (US)- Japan- Germany, France, UK, Italy and Spain (EU5), also with EU regional prediction- Brazil, Russia, India and China (BRIC nations).There you find regions and countries with highest revenues, demands and potential sales growth. Stay ahead, then, for information, finding international prospects for that promoting and selling to doctors and other medical practitioners.And what events change that market? Our work shows you, discussing trends and needs.Developments, challenges and events influencing contract sales organisationsThe report also explains issues affecting the CSO industry and market from 2015:- Outsourced and in-house sales reps - trends and emerging sales models, including multiple channels (multichannel marketing to medical professionals)- Services CSOs offer and benefits to drug companies outsourcing medical sales- Maturing brands and product launches, including flexibility in field sales teams- Legislation and new market access requirements for pharma sales representatives - regulatory outlooks- Changes to online marketing and potential for recent and emerging IT technologies- Risk-sharing agreements, key account management (KAM), key opinion leaders (KOLs) and medical science liaison (MSL).And you explore these influences, too, among others:- Smartphones and tablets for detailing - advances in communication technology- Closed loop marketing (CLM), cloud computing and customer relationship management (CRM), including social media and big data- Changes to in-house sales staffing levels - rising demand for outsourcing service providers- Demand for inside and outside medical sales teams, as well as increasing needs for contact centres- Strategic partnering and CSO consolidation - links, networks and alliances- Promotion of biologics, biosimilars, orphan drugs and other specialty medicines.There investigate what stimulates and restrains competitors in that industry, and affects its results. You also get SWOT and STEP analyses.Companies and potential for sales increases - what gains are possible?That study predicts the world market for pharma contract selling will rise to $6.46bn in 2019, with strong revenue expansion from 2015 to 2025. Those services have increasing demand.There large pharma service contractors and specialists can prosper, expanding business. Our new analysis shows you gains possible.So what happens next? In particular, that report assesses these companies' activities:- Quintiles- inVentiv Health- UDG Healthcare- Publicis Touchpoint Solutions- OnCall- PDI.There you analyse participants' results, capabilities and outlooks. You also see interviews with three firms - OnCall, Apodi and Hilver. Discover what pharma outsourcing providers do, say and think, helping you stay ahead.Ways Pharma Contract Sales Industry and Market: Trends and Forecasts 2015-2025 helpsIn these six main ways, our new study benefits your research, analyses and decisions:- World revenue for contract sales to 2025, with that market also divided into 11 service submarket forecasts - assess prospects for pharma business expansion- Forecasts to 2025 for 11 national markets in the Americas, Europe and Asia - investigate developed and developing countries for expanding commercial potentials- Outlooks for established, rising and emerging service providers - explore companies' results, capabilities, partnerships, technologies, portfolios and strategies- Competition and opportunities - investigate what shapes that medical promotion industry's future, including ways to develop business in drug selling- Analysis of what stimulates and restrains that medical outsourcing - assess commercial challenges and strengths, helping you compete and gain advantages- Interviews with three companies - OnCall, Apodi and Hilver - discover what other authorities in that field think, say and do, helping you stay ahead.Knowledge found nowhere else, helping your searches, plans and analysesOur report gives independent analysis. With that data you're less likely to fall behind in knowledge or miss opportunity. See what's possible, getting independent business analysis.Through your choice now, discover how you could save time and effort. And, on selling pharmaceuticals, help your planning, decisions and authority.Predictions for outsourced drug promoting - gain by trying our investigationOur new study is for everyone investigating medical promotions and selling. There find revenue forecasting to 2025, with discussions and other information. Avoid missing out. Instead get that report here now.

McKesson Corporation to buy the EUR408m pharmaceutical distribution division of UDG Healthcare
M2 - Fri Sep 18, 5:11AM CDT
Healthcare services company McKesson Corporation (NYSE:MCK) reported on Friday that it has entered into an agreement to acquire the pharmaceutical distribution division of UDG Healthcare (UDG) based in Northern Ireland (United Drug Sangers) and the Republic of Ireland (United Drug) for a purchase price of EUR408m in cash.
MCK: 193.44 (-0.41)

McKesson Announces Agreement to Purchase the Pharmaceutical Distribution Division of UDG Healthcare plc
BusinessWire - Fri Sep 18, 3:37AM CDT
--Acquisition will add a leader in pharmaceutical distribution across the Republic of Ireland and Northern Ireland to McKesson's European business.
MCK: 193.44 (-0.41)

The Global Market for Stick Packaging is Projected to Reach $316.61 Million by 2020
M2 - Tue Jun 16, 5:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mt8m7n/stick_packaging) has announced the addition of the "Stick Packaging Market by Material, Application, & by Region - Trends & Forecasts to 2020" report to their offering. The stick packaging market has expanded owing to developments in the flexible packaging industry. The demand for stick packaging is growing at a significant pace and is projected to grow at an even higher rate in the near future. With the rising population and increased incomes of people, the use of packaged products is booming, and consequently, so is the stick packaging market. The stick packaging market can be classified into three main categories based on application: food & beverages, pharmaceuticals, consumer goods, nutraceuticals, and others. The market for stick packaging is observed to be mature in developing economies such as Europe and North America. The reason behind this is the rapid growth in the packaging sector. The Asia-Pacific region formed the second-largest market, with a share of 30%. It is projected to be the fastest-growing market for stick packaging from 2015 to 2020. The global stick packaging market is marked with intense competition due to the presence of a large number of both, big and small firms. New product launches, mergers & acquisitions, and partnerships & expansions are the key strategies adopted by market players to ensure their growth in the market. Companies Mentioned: - Amcor Limited (Australia) - Bosch Packaging Technology - Constantia Flexibles (Austria) - Fres-Co System Inc. - Huhtamaki OYJ (Finland) - Mondi Group (South Africa) - Oystar Group - Sonoco Products Company (U.S.) - UDG Healthcare PLC - Winpak For more information visit http://www.researchandmarkets.com/research/mt..._packaging About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
SON: 51.47 (-0.40)

Pharma Contract Sales Industry and Market: Trends and Forecasts 2015-2025
PR Newswire - Tue Jun 02, 2:29PM CDT
Report DetailsOutsourced selling of medicines - how to find trends, opportunities and potential revenuesWhat's the future of outsourcing pharma sales activities? For prescription drugs, get new forecasts for contracted promotional activities. Stay ahead, then, for data. There you explore business results, progress, trends, strategies and predicted revenues.Visiongain's updated report shows what's possible for those pharmaceutical services. Avoid missing out on opportunities. Instead explore advances in medical detailing and potential gains for contract sales organisations (CSOs).Please read on, then, to investigate that expanding healthcare industry, seeing what its future could be worth. For that outsourcing you assess expected developments.Forecasts and other information showing opportunity in pharmaceutical sales contractingProgress worldwide in healthcare expands use of out-contracted services for promoting and selling human medicines. There see what's possible.Besides forecasting revenues to 2025, the new analysis shows historical data, recent results, growth rates and market shares. There you gain feel for companies' outlooks and potentials. You also get 77 tables, 64 charts and three interviews with that industry.Knowledge to help your work and save time, benefiting your influenceOur study shows you revenue predictions to 2025 at overall world, submarket and national level. For those service offerings you investigate where money lies. Find what's happening.And avoid struggles to find business information on outsourced drug selling. Our report helps your research, analyses and decisions for medical sales. Save time, too, and stay ahead.Also - by gaining in knowledge of the present and future - benefit your authority through increased technological and commercial insight.And the following sections highlight, in detail, what the new investigation gives you.Forecasting of that world market and its segments - what's likely to happen?What're the secrets of that industry's progress? And what's its potential? Discover in our report overall world revenue to 2025 for contract pharma sales operations.Also see individual predictions of revenues to 2025 for 11 submarkets at world level:- Field sales (detailing)- Non-personal promotion, also with sub-forecasting for teledetailing, e-detailing and other selling functions- Medical education- Sample management activities- Other outsourced promotional services.And get forecasts by therapeutic application:- Cardiovascular disease therapies- Metabolic disorder treatments- Cancer-treating agents.There you assess prospects for outsourced medicine sales, hearing where you can gain. Investigate competition and increasing revenues. So discover lucrative possibilities for syndicated pharma sales teams and related promotional activities.Our investigation also shows you geographical predictions for CSOs and their teams.Healthcare in national markets - commercial outlooks for medical sales contractingThat study shows countries having great potential for those outsourced and off-shored selling operations. See where and how you could profit, assessing predicted revenues.Our analyses show you individual revenue forecasts to 2025 for 11 national markets:- United States (US)- Japan- Germany, France, UK, Italy and Spain (EU5), also with EU regional prediction- Brazil, Russia, India and China (BRIC nations).There you find regions and countries with highest revenues, demands and potential sales growth. Stay ahead, then, for information, finding international prospects for that promoting and selling to doctors and other medical practitioners.And what events change that market? Our work shows you, discussing trends and needs.Developments, challenges and events influencing contract sales organisationsThe report also explains issues affecting the CSO industry and market from 2015:- Outsourced and in-house sales reps - trends and emerging sales models, including multiple channels (multichannel marketing to medical professionals)- Services CSOs offer and benefits to drug companies outsourcing medical sales- Maturing brands and product launches, including flexibility in field sales teams- Legislation and new market access requirements for pharma sales representatives - regulatory outlooks- Changes to online marketing and potential for recent and emerging IT technologies- Risk-sharing agreements, key account management (KAM), key opinion leaders (KOLs) and medical science liaison (MSL).And you explore these influences, too, among others:- Smartphones and tablets for detailing - advances in communication technology- Closed loop marketing (CLM), cloud computing and customer relationship management (CRM), including social media and big data- Changes to in-house sales staffing levels - rising demand for outsourcing service providers- Demand for inside and outside medical sales teams, as well as increasing needs for contact centres- Strategic partnering and CSO consolidation - links, networks and alliances- Promotion of biologics, biosimilars, orphan drugs and other specialty medicines.There investigate what stimulates and restrains competitors in that industry, and affects its results. You also get SWOT and STEP analyses.Companies and potential for sales increases - what gains are possible?That study predicts the world market for pharma contract selling will rise to $6.46bn in 2019, with strong revenue expansion from 2015 to 2025. Those services have increasing demand.There large pharma service contractors and specialists can prosper, expanding business. Our new analysis shows you gains possible.So what happens next? In particular, that report assesses these companies' activities:- Quintiles- inVentiv Health- UDG Healthcare- Publicis Touchpoint Solutions- OnCall- PDI.There you analyse participants' results, capabilities and outlooks. You also see interviews with three firms - OnCall, Apodi and Hilver. Discover what pharma outsourcing providers do, say and think, helping you stay ahead.Ways Pharma Contract Sales Industry and Market: Trends and Forecasts 2015-2025 helpsIn these six main ways, our new study benefits your research, analyses and decisions:- World revenue for contract sales to 2025, with that market also divided into 11 service submarket forecasts - assess prospects for pharma business expansion- Forecasts to 2025 for 11 national markets in the Americas, Europe and Asia - investigate developed and developing countries for expanding commercial potentials- Outlooks for established, rising and emerging service providers - explore companies' results, capabilities, partnerships, technologies, portfolios and strategies- Competition and opportunities - investigate what shapes that medical promotion industry's future, including ways to develop business in drug selling- Analysis of what stimulates and restrains that medical outsourcing - assess commercial challenges and strengths, helping you compete and gain advantages- Interviews with three companies - OnCall, Apodi and Hilver - discover what other authorities in that field think, say and do, helping you stay ahead.Knowledge found nowhere else, helping your searches, plans and analysesOur report gives independent analysis. With that data you're less likely to fall behind in knowledge or miss opportunity. See what's possible, getting independent business analysis.Through your choice now, discover how you could save time and effort. And, on selling pharmaceuticals, help your planning, decisions and authority.Predictions for outsourced drug promoting - gain by trying our investigationOur new study is for everyone investigating medical promotions and selling. There find revenue forecasting to 2025, with discussions and other information. Avoid missing out. Instead get that report here now.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 135

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 220

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 210

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 318

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 269

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 283

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 406

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 180

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 103

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 235

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading

Top 5 Most Recently Viewed Articles

Kulicke & Soffa Announces Conference Call for Fiscal Results

Updated Category News Views 122

Kulicke & Soffa Schedules Conference Call Kulicke and Soffa Industries, Inc. (NASDAQ: KLIC), a leading name in semiconductor assembly technology, has announced a conference call to discuss its third fiscal quarter financial results and business outlook. The call is set for a future date, highlighting the company's commitment to transparency and communication with its...

Continue Reading
ARMOUR Residential REIT Launches Major Stock Offering for Growth

Updated Category News Views 162

ARMOUR Residential REIT Enters Public Stock Offering ARMOUR Residential REIT, Inc. (NYSE: ARR and ARR-PRC) has officially announced an underwritten public offering of 18,500,000 shares of common stock. The company is poised to grant underwriters an additional option to purchase up to 2,775,000 shares, making this a significant move for ARMOUR as it aims to enhance its...

Continue Reading
Celebrate Mother's Day with a Unique Brunch at Cannon + Belle

Updated Category News Views 195

Cannon + Belle Offers a Memorable Mother's Day Brunch Cannon + Belle at Hilton Austin is excited to announce an elevated Mother's Day brunch that promises to create unforgettable memories. This year, the restaurant will be hosting a special brunch event aimed at honoring mothers and all they do. With an impressive menu curated by the talented Chef Gereamy Cater, guests...

Continue Reading
Figma's Shares Surge in IPO But Valuation Remains a Concern

Updated Category News Views 244

Figma's Impressive IPO Performance Figma Inc. (NYSE: FIG) has captured significant investor attention following its explosive debut in the stock market. After launching its initial public offering, the company's shares skyrocketed by over 250%, marking a remarkable milestone for the firm. The stock began trading at a price of $33 per share, leading to approximately $1.2...

Continue Reading
Journey Medical Corporation's Emrosi Launch for Rosacea Relief

Updated Category News Views 215

Journey Medical Corporation Introduces Emrosi for Rosacea Treatment Journey Medical Corporation, a key player in the dermatological pharmaceutical industry, has recently launched Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules), designed for the effective treatment of rosacea. The product, featuring a unique formulation of 10 mg immediate release and...

Continue Reading